Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Cut by Arete Wealth Advisors LLC

Arete Wealth Advisors LLC lessened its position in Edwards Lifesciences Co. (NYSE:EW) by 4.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,439 shares of the medical research company’s stock after selling 150 shares during the period. Arete Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $225,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Lantz Financial LLC boosted its holdings in Edwards Lifesciences by 25.3% during the second quarter. Lantz Financial LLC now owns 3,236 shares of the medical research company’s stock worth $299,000 after buying an additional 654 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Edwards Lifesciences by 38.2% during the 2nd quarter. Blue Trust Inc. now owns 5,051 shares of the medical research company’s stock valued at $483,000 after acquiring an additional 1,397 shares during the last quarter. Raymond James & Associates boosted its stake in shares of Edwards Lifesciences by 2.8% during the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock worth $168,597,000 after acquiring an additional 50,124 shares in the last quarter. Williams Financial LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth $201,000. Finally, Raymond James Financial Services Advisors Inc. raised its position in shares of Edwards Lifesciences by 0.9% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 1,154,757 shares of the medical research company’s stock worth $106,665,000 after purchasing an additional 10,176 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $73.32 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $43.24 billion, a PE ratio of 10.58, a PEG ratio of 3.63 and a beta of 1.12. The firm’s 50 day moving average price is $69.42 and its 200 day moving average price is $73.99. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.59 EPS. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EW. Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Piper Sandler decreased their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Royal Bank of Canada upped their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. Finally, The Goldman Sachs Group lifted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.65.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,000 shares of company stock valued at $2,323,150 over the last quarter. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.